“This $2.5 million placement shows the confidence of our strategic investors in Emyria’s vision and potential,” he said.“This investment enables us to advance multiple, innovative treatment development programs as well as deliver scalable, evidence-generating psychedelic-assisted therapy with our specialist partners. We are well set to deliver on our vision of improving the lives of patients with mental health and neuroscience challenges while generating enduring value for our Shareholders.”
that reads very well to me
Add to My Watchlist
What is My Watchlist?
